Orchid Pharma has reported its audited financial results for the quarter and year ended March 31, 2026. The company achieved standalone annual revenue of ₹81,132.73 lakh and a profit of ₹4,520.79 lakh for the year. Strategic milestones include the full repatriation of its antibiotic molecule EXBLIFEP following the 100% acquisition of Allecra Therapeutics’ assets and the appointment of a new internal auditor for the upcoming 2026-27 fiscal year.
Annual Financial Performance
For the financial year ended March 31, 2026, Orchid Pharma recorded a consolidated total income of ₹84,650.06 lakh. The standalone financial results highlight a resilient performance with total revenue from operations reaching ₹81,132.73 lakh. The company’s profit for the year stood at ₹4,520.79 lakh on a standalone basis, reflecting its operational focus and efficient cost management strategies throughout the year.
Strategic Acquisitions and Market Expansion
Orchid Pharma has significantly strengthened its global footprint through key acquisitions. The company successfully completed the acquisition of 100% of the assets of Allecra Therapeutics GmbH (Germany) and Allecra Therapeutics SAS (France) in late 2025. This move grants the company full global ownership of Enmetazobactam (EXBLIFEP), marking the successful repatriation of this innovative antibiotic molecule to India. Furthermore, the company expanded its European operations by acquiring 100% of the share capital of Weilchensee 1272. V V GmbH, now operating as Orchid Pharma Europe GmbH.
Corporate Governance and Operational Updates
The company continues to advance its infrastructure goals, with ₹7,302 lakh already utilized from the Qualified Institutional Placement (QIP) proceeds for the Jammu Manufacturing Facility. In terms of governance, the Board has approved the appointment of M/s. T R Chadha & Co., LLP as the internal auditor for the 2026-27 financial year. Additionally, the company is awaiting the final order from the National Company Law Tribunal (NCLT) regarding the proposed amalgamation of its holding company, Dhanuka Laboratories Limited.
Source: BSE
